In the News

Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine. The landmark data support the foundation of precision oncology by creating a treatment option for a genetically defined cancer while continuing to validate the concept that comprehensive molecular profiling should be strongly considered in people of all ages with advanced solid tumors.

MSK doctors and scientists are leading the charge to find new and innovative ways to treat metastatic brain cancer.

MSK’s Supportive Care Service aims to improve quality of life for all people with cancer.

Meet three people who were treated as part of a clinical trial for melanoma at Memorial Sloan Kettering.

A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.

The American Heart Association recently issued a statement about the risk of cardiovascular disease for women with breast cancer.

The study represents 20 years of research at MSK.

Doctors are developing treatment strategies that target the androgen receptor, which is found in many triple-negative breast cancers.

MSK's Neil Iyengar will present at the American Association for Cancer Research special conference about the risk of invasive breast cancer. A new study found that the risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat. These findings suggest that having a normal BMI can provide false reassurance regarding the risk of breast cancer associated with body fat, and they also highlight the potential role of physical activity and exercise even in those who are at a normal weight. For expert interviews, please contact Nicole H. McNamara at [email protected].

The online resource will serve as a benchmark for researchers studying metabolism and cancer.